Drug assessment at a glance: A25-163[1]

Guselkumab (plaque psoriasis in children and adolescents)

25 August 2026

[1] This is a courtesy translation of the summary provided as a service by IQWiG. For further information on the subject matter and the result of the assessment, please refer to the dossier assessment for Project A25-163. The G-BA decides on the added benefit.

Research question for the benefit assessment

Population	Children and adolescents from the age of 6 years with moderate to severe plaque psoriasis for whom systemic therapy is an option
Intervention	guselkumab
Comparator	adalimumab or etanercept or ixekizumab or secukinumab or ustekinumab
Outcomes	At least one patient-relevant outcome

Overview of positive and negative effects

	Size of the effects		Informative value of the effects	
Mortality	∅		–	
Morbidity	∅		–	
Symptoms	∅		–	
Health-related quality of life	∅		–	
Side effects	∅		–	
	∅	No (suitable) data	–	Not applicable
	↔	No advantage or disadvantage	★	Low
	↑ / ↓	Small advantage/disadvantage	★★	Moderate
	↑↑ / ↓↓	Moderate advantage/disadvantage	★★★	High
	↑↑↑ / ↓↓↓	Large advantage/disadvantage		

Overall: No advantage or disadvantage (no suitable data)

Evidence base and noteworthy aspects

- No suitable data were available.
- The dossier presented data from a subpopulation of the partially open-label, randomized controlled trial PROTOSTAR, which compared guselkumab with etanercept. This study was not suitable for answering the research question because
  - the definition of the severity of the disease in the study did not guarantee suitability for treatment with etanercept,
  - the dosage of guselkumab in the study did not, in some cases, correspond to the summary of product characteristics,
  - in the study, patients who did not respond potentially continued etanercept beyond Week 12 as an off-label treatment, and
  - the 16-week observation period was too short for the given therapeutic indication.

References

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Guselkumab (Plaque-Psoriasis bei Kindern und Jugendlichen); Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung [online]. 2026 [Accessed: 11.05.2026]. URL: https://doi.org/10.60584/A25-163.

Gemeinsamer Bundesausschuss. Nutzenbewertungsverfahren zum Wirkstoff Guselkumab (Neues Anwendungsgebiet: mittelschwere bis schwere Plaque-Psoriasis; 6 bis < 18 Jahre) [online]. 2026 [Accessed: 11.05.2026]. URL: https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1297/.

English translations for this project are published at https://www.iqwig.de/en/projects/a25-163.html.

Publisher details

Publisher

Institute for Quality and Efficiency in Health Care (IQWiG)

Address

Siegburger Str. 237
50679 Köln
Germany

Phone: +49 221 35685-0
Fax: +49 221 35685-1
Email: info@iqwig.de
Internet: www.iqwig.de